Non-Oral Formulations

Question 1

Transdermal Patch

Answer 1

• A combined hormone contraceptive
• Available as Ortho Evra (35mg ethinyl estradiol and 150mcg or 200mcg norelgestromin - active form of norgestimate) daily x 21 days, then followed by patch-free week
• May experience withdrawal bleeding during patch-free week
• CON = higher exposure to estrogen over time
• Not very effective in obese patients (over 198 lbs/90 kg)

Question 2

Vaginal Ring

Answer 2

• Available as NuvaRing (15mcg ethinyl estradiol and 120mch etonogesterel) dayil x 21 days, followed by ring-free week
• PRO = Less estrogen exposure, so less estrogen-related side effects

Question 3

Depot Injection

Answer 3

• Available as Depo-subQ Provera [104mg/0.65ml] or Depo-Provera (IM) [150mg/ml]
• Contains medroxyprogesterone acetate (progestin-only)
• Given every 3 months
• CONS = Initially more unpredictable spotting/breakthrough bleeding, weight gain, takes time to get pregnant after stopping, decrease bone density
• PROS = After 1 year, ammenorhea